Cheng Hui-Teng, Xu Xiaoqi, Lim Paik Seong, Hung Kuan-Yu
Department of Internal Medicine, National Taiwan University Hospital Hsin-Chu Biomedical Park Branch, Zhubei City, Taiwan
Department of Internal Medicine, National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu City, Taiwan.
Diabetes Care. 2021 Jan;44(1):89-97. doi: 10.2337/dc20-1913. Epub 2020 Nov 17.
The annual risk among patients with diabetes of reaching end-stage renal disease (ESRD) is largely unknown worldwide. This study aimed to compare the incidence of diabetes-related ESRD by creating a global atlas during 2000-2015.
The annual incidence of ESRD among patients with diabetes was calculated as the quotient of the number of incident ESRD patients with diabetes divided by the total number of patients with diabetes after subtraction of the number with existing ESRD. The estimated ESRD prevalence and annual incidence were validated with use of the data provided by Fresenius Medical Care, Germany, and previously reported data, respectively.
Data were obtained from 142 countries, covering 97.3% of the world population. The global percentage of the prevalent ESRD patients with diabetes increased from 19.0% in 2000 to 29.7% in 2015 worldwide, while the percentage of incident ESRD patients due to diabetes increased from 22.1% to 31.3%. The global annual incidence of ESRD among patients with diabetes increased from 375.8 to 1,016.0/million with diabetes during 2000-2015. The highest average rates were observed in the Western Pacific Region. Comparatively, the rates of incident ESRD among European patients with diabetes ranged from one-half (309.2 vs. 544.6) to one-third (419.4 vs. 1,245.2) of the rates of the Western Pacific population during 2000-2015.
Great and nonrandom geographic variation in the annual rates among patients with diabetes of reaching ESRD suggests that distinct health care, environmental, and/or genetic factors contribute to the progression of diabetic kidney disease. Measures to prevent and treat diabetes-related ESRD require better patient susceptibility stratification.
全球范围内,糖尿病患者发展至终末期肾病(ESRD)的年度风险在很大程度上尚不明确。本研究旨在通过创建2000 - 2015年的全球图谱来比较糖尿病相关ESRD的发病率。
糖尿病患者中ESRD的年发病率计算方法为,糖尿病ESRD新发病例数除以糖尿病患者总数(减去已有ESRD的患者数)的商。估计的ESRD患病率和年发病率分别使用德国费森尤斯医疗集团提供的数据以及先前报告的数据进行验证。
数据来自142个国家,覆盖全球97.3%的人口。全球糖尿病ESRD患者的患病率从2000年的19.0%增至2015年的29.7%,而糖尿病导致的ESRD新发病例的比例从22.1%增至31.3%。2000 - 2015年期间,糖尿病患者中ESRD的全球年发病率从每百万糖尿病患者375.8例增至1016.0例。西太平洋地区的平均发病率最高。相比之下,2000 - 2015年期间,欧洲糖尿病患者中ESRD的发病率是西太平洋地区人群发病率的二分之一(309.2对544.6)至三分之一(419.4对1245.2)。
糖尿病患者发展至ESRD的年度发病率存在巨大且非随机的地理差异,这表明不同的医疗保健、环境和/或遗传因素导致了糖尿病肾病的进展。预防和治疗糖尿病相关ESRD的措施需要更好地对患者易感性进行分层。